Ahn MJ - Search Results

1

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).

Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y. Okada M, et al. Among authors: ahn mj. Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985. Clin Cancer Res. 2022. PMID: 35294546 Free PMC article.

2

Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.

Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K. Park BB, et al. Among authors: ahn js, ahn mj. Invest New Drugs. 2008 Aug;26(4):387-92. doi: 10.1007/s10637-008-9126-3. Epub 2008 Mar 27. Invest New Drugs. 2008. PMID: 18368291 Clinical Trial.

3

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Jänne PA, Park K. Ahn MJ, et al. Among authors: ahn js. Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608. Clin Cancer Res. 2008. PMID: 18559606 Clinical Trial.

4

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Chang MH, et al. Among authors: ahn js, ahn mj. Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17. Cancer Chemother Pharmacol. 2009. PMID: 19221753 Clinical Trial.

5

Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Kim HS, et al. Among authors: ahn js, ahn mj. Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25. Oncology. 2009. PMID: 19246948

6

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K. Uhm JE, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2009 Sep;4(9):1136-43. doi: 10.1097/JTO.0b013e3181b270a7. J Thorac Oncol. 2009. PMID: 19687764 Free article. Clinical Trial.

7

Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.

Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH. Chung MK, et al. Among authors: ahn yc, ahn mj. Clin Cancer Res. 2009 Sep 15;15(18):5861-8. doi: 10.1158/1078-0432.CCR-08-3290. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737951

8

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.

Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH. Lee DH, et al. Among authors: ahn js, ahn mj. Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719. Cancer. 2010. PMID: 19904804 Free article. Clinical Trial.

9

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Lee DH, et al. Among authors: ahn js, ahn mj. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145166 Clinical Trial.

10

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Sun JM, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. J Thorac Oncol. 2010. PMID: 20195170 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

772 results

Search Page

Filters